This year the ECMC Junior Investigators Network Group (JING) hosted its hugely successfully JING: Training the Next Generation residential in Glasgow. Now in its fifth year, the two-day meeting saw over 90 Network members come together to share their knowledge and experience in running early-phase clinical trials.
Researchers at Manchester and ICR ECMCs have found that tumour necrosis in patients with bladder cancer does not affect how they respond to drugs used in combination with radiotherapy. This may mean that a drug and radiotherapy combination can be used in bladder cancer treatment, regardless of necrosis state.
UCLH has recruited the first patient in Europe to a major new study to see if a combination of cancer drugs can benefit patients with a rare bone cancer. Patients over the age of 12 years with Ewing sarcoma, which affects fewer than 100 patients a year in the UK but is the second most common primary bone tumour in teenagers and young adults, will be eligible to take part in a study exploring the effects of combining a new drug called Niraparib with drugs used for treatment of Ewing sarcoma called Temozolomide (Arm 1) or Irinotecan (Arm 2).
Dr Gillian Smith from the Division of Cancer Research at Dundee ECMC recently swapped her lab coat for a week in Westminster. The visit was part of the Royal Society’s pairing scheme to build bridges between scientists and policy makers and parliamentarians.
As we start the new year, thoughts of conference attendance and publications present themselves. As a reminder we ask that all Grant holders adhere to the terms and conditions for all CRUK grants and endorsements with regards to publications as follows:
Requirements for publications:
Cancer Research UK (CRUK) is committed to providing a supportive, flexible training environment for clinical academics.
They've worked with funders from across the medical research community to develop principles and obligations setting out what they expect from those responsible for clinical training, trainees and funders across the UK.
CRUK wants to ensure that academic training is acknowledged, recognised and integrated with clinical training and work, and that clinical academics feel valued.
Might somatostatin receptor (SSTR) expression by circulating tumour cells (CTCs) in patients with neuroendocrine tumours (NETs) be a useful biomarker for evaluating SSTR-targeted therapies?
Neuroendocrine tumours have diverse biological and clinical features and are characterised histologically by high expression of somatostatin receptors, of which five different subtypes have been identified. Their unique expression profiles have been exploited for both diagnostic and therapeutic applications.